Brazil: Pharma Trademarks In Brazil: Going To Court To Get Your Name

Many multinational drug makers are active in Brazil. However, they must often forgo their first choice for a brand and move forward with less desirable options because of the difficulties during the registration process. New rules on the approval of medicine names, together with easier access to Brazilian courts, can help with new strategies for pharmaceutical brands in the country.

When selecting and clearing a new name, drug makers must still choose a brand that can be registered as a trademark before the Brazilian Patent and Trademark Office (INPI) and be approved by the Brazilian Federal Drug Agency (ANVISA). However, the lack of communication between the agencies, which have independent registration processes, previously made it hard to predict if a name would be accepted and approved in both instances.

In December 2017, ANVISA rolled out a new resolution that specifically requires in the approval process a search on the INPI's database to confirm the availability of a trademark registration. Therefore, the full set of procedures to approve a drug name by ANVISA now involve searches on the agency's internal database, external medicine databases and the INPI database, to access the availability of the proposed name in terms of graphic and phonetic similarities with existing names, risk of error and the level of safety of the name in terms of prescriptions, dispensing, administration or use.

Despite the apparent progress in communication between the agencies, it is still unclear how the ANVISA examiners are being trained to decide on the approval of a new drug name in the face of a trademark registration. At the still early stages of the new guidelines it is useful to review the existing criteria established to approve a new drug name. These are:

  • Purpose of use of the medicine;
  • How the medicine should be used;
  • How the medicine works;
  • What are the benefits of the medicine;
  • The risks associated with the use of the medicine;
  • What steps can be taken to ensure safe use of medicine; and
  • The intrinsic characteristics of the medicine

If the above standards are applied, ANVISA examiners will review the risk of confusion between similar drug names not based on their graphic and phonetic aspects only, but also on how they will be used in practice, including associated risks and benefits of the medicine.

In the case of pharmaceutical brands registered at the INPI with a broad specification of goods, will the ANVISA examiners be able to confirm the purpose of the medicine and its other characteristics?

If approval by ANVISA is rejected based on the non-availability of the drug name as a trademark, can drug makers take other steps at the INPI to ensure a successful registration process? Would further information on the purpose and characteristics of the medicine, which may have been registered at the INPI with a broad specification of goods, be sufficient to overcome a denial by the ANVISA? Can the approval process at the ANVISA be put on hold until a trademark registration is secured at the INPI?

These are all new questions that will have to be addressed with the new link between the drug name approval and trademark registration processes. As with any new set of guideless, one can expect that some decisions will be contradictory and so challengeable at Brazilian courts.

It is noteworthy that the judicial review of administrative decisions by either the ANVISA or the INPI is widely available in Brazil. This means that drug makers can consider adding litigation to secure those first-choice names to be marketed in Brazil.

While there is a common sense that litigating against government entities (like ANVISA and INPI) is costly and time consuming, a study covering almost 1,000 decisions issued by the Federal Court of Rio de Janeiro on trademark cases shows a surprising success rate. Moreover, recent modifications to the court's structure and the civil procedure rules have made the timeframe of these lawsuits much quicker than administrative appeals at the INPI. And the costs associated with this kind of litigation are substantially lower than in comparison to other countries.

Due to the concentration of lawsuits against the INPI at the Federal Court of Rio de Janeiro there are now five district judges and two groups of appellate judges assigned to review these cases, which led to an upgrade of the technical qualification of these courts and consequently led to better grounded decisions.

Based on all decisions rendered by these specialised judges between 2015 and 2016, the overall chances of overturning the rejection of a trademark application are 50.8% at trial level. The chances of securing this registration at appellate level are even better: 67.4%. The overall likelihood of cancelling a trademark registration granted by the INPI is 45.8% at trial level and 36.6% if the cases go to appellate level.

This unofficial data was collected independently by review of the existing cases and decisions.

A deeper analysis of the case law shows that the Federal courts have an accommodating understanding about the coexistence of similar trademarks and are less stringent on the analysis of distinctiveness than the INPI. This is one of the reasons why there are slightly better chances of overturning a rejection of a trademark application than to cancel trademark registrations.

Perhaps a drug name will have already reached trademark registration, but it may not be approved by ANVISA. Or vice versa. Is it worth challenging one of the administrative decisions to secure a first-choice drug name? It is certainly an option.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions